CHMP recommends wider labels for Pfizer's Revatio, Lilly's Alimta and GSK's H5N1 vaccine
This article was originally published in Scrip
Executive Summary
The CHMP has recommended broader indications for Pfizer's antihypertensive Revatio (sildenafil), Lilly's antifolate Alimta (pemetrexed disodium) and GlaxoSmithKline's prepandemic H5N1 vaccine Prepandrix, during its May meeting.